Skip to content
The Nexus
DossierENTITY

Talvey

Coverage of Talvey in the Nexus archive.

Earliest in view: Jun 13 · 10:00 UTCMost recent: Jun 13 · 10:00 UTC
Co-mentioned in this coverage
Talquetamabtopic1daratumumabtopic1Darzalextopic1pomalidomidetopic1Pomalysttopic1multiple myelomatopic1MedPage Todayorganization1
Recent coverage
  • HEALTHJun 13 · 10:00 UTCMEDPAGE TODAY
    Talquetamab Regimens Boost Survival in Multiple Myeloma

    A phase III trial showed that Talquetamab (Talvey) combined with daratumumab (Darzalex) and optionally pomalidomide (Pomalyst) significantly improved survival outcomes for patients with relapsed or refractory multiple myeloma compared to an active regimen.